Navigation Links
Keryx Biopharmaceuticals Announces Phase 2 Data for KRX-0401 (Perifosine) in Hodgkin's Lymphoma Presented at ASH Meeting
Date:12/13/2011

esults

Clinical response data showed that baseline pErk and pAkt levels were significantly higher in responsive patients as compared to unresponsive patients. The pErk and pAkt levels measured after 60 days of therapy with perifosine combined with sorafenib were significantly reduced in responsive patients. The median baseline value of pErk and pAkt efficiently discriminated responsive and unresponsive patients which was associated with a significantly improved median PFS for patients with baseline pErk ≥43% and/or pAkt > 23%.

Conclusions

Refractory/relapsed Hodgkin Lymphoma patients with increased baseline levels of pErk and pAkt demonstrated increased PFS when treated with perifosine in combination with sorafenib.

A copy of the above referenced abstract can be viewed online through the ASH meeting website, http://ash.confex.com/ash/2011/webprogram/start.html.

KRX-0401 is currently in Phase 3 clinical development for both refractory advanced colorectal cancer and multiple myeloma, and in Phase 1 and 2 clinical development for several other tumor types. Each of the KRX-0401 Phase 3 studies is being conducted under a Special Protocol Assessment (SPA) agreement with the Food and Drug Administration (FDA).

KRX-0401 (perifosine) is in-licensed by Keryx from Aeterna Zentaris Inc. in the United States, Canada and Mexico.

About Hodgkin's  Lymphoma

Hodgkin's Lymphoma (HL) is a cancer of the immune system. The two major types of HL are classical HL and nodular lymphocyte-predominant HL. The most common symptom of HL is the painless swelling of the lymph nodes in the neck, underarm or chest. Other symptoms include fever, weight loss, fatigue, or night sweats. According to the National Cancer Institute, there will be 8,830 news cases of HL in the United States in 2011, resulting in 1,300 deaths.

About Kery
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Keryx Biopharmaceuticals Announces Highlights from Zerenex™ (ferric citrate) Poster Presentations at American Society of Nephrology Kidney Week 2011 Annual Meeting
2. Keryx Biopharmaceuticals to Present at Lazard Capital Markets 8th Annual Healthcare Conference
3. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2011 Financial Results
4. Keryx Biopharmaceuticals, Inc. to Host Conference Call on Third Quarter 2011 Financial Results
5. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
6. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2011 Financial Results
7. Keryx Biopharmaceuticals, Inc. to Host Conference Call on Second Quarter 2011 Financial Results
8. Keryx Biopharmaceuticals, Inc. Prices Common Stock Offering
9. Keryx Biopharmaceuticals Announces Commencement of Phase 3 Program of Ferric Citrate (Zerenex™) in Japan by Partner, Japan Tobacco and Torii Pharmaceutical
10. Keryx Biopharmaceuticals Announces Two Poster Presentations on KRX-0401 (Perifosine) at Upcoming American Association for Cancer Research (AACR) Annual Meeting
11. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2010 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/30/2014)... 2014  Boston Scientific has released the primary ... Heart Failure (NECTAR-HF) clinical trial, the first and ... stimulation (VNS) for the treatment of heart failure ... and Cardiology and Director of the Clinical Investigation ... et de la Recherche Medicale presented the results ...
(Date:8/30/2014)... , Aug. 30, 2014   Royal Philips  (NYSE: ... Affiniti, a new ultrasound system designed to enable ... of increasing patient volumes and cost pressures. Making its ... in Barcelona this week, ... more patients with fewer resources deliver high quality patient ...
(Date:8/29/2014)... -- Market Research Report on Global and Chinese ... and in-depth market survey on Global and ... firstly reviews the basic information of X-Ray Crystallography ... The report then explores global and China,s top ... specification, capacity, Production value, and market share etc. ...
Breaking Medicine Technology:Boston Scientific Announces Primary Endpoint Results of NECTAR-HF Clinical Trial 2Boston Scientific Announces Primary Endpoint Results of NECTAR-HF Clinical Trial 3Boston Scientific Announces Primary Endpoint Results of NECTAR-HF Clinical Trial 4Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 2Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 3Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 4X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 2X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 3X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 4X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 5
... MINNEAPOLIS, Oct. 4 BridgePoint Medical, Inc., a ... catheter-based systems for chronic total occlusion (CTO) recanalization, ... 16 center, 147 patient U.S. FAST-CTOs (Facilitated Antegrade ... Occlusions) study was designed to assess the safety ...
... a blocked heart artery isn,t the only procedure that ... in a thigh artery and into a heart artery. ... (Logo: http://photos.prnewswire.com/prnh/20100222/AHSALOGO ) ... process of creating a hole in an "access artery" ...
Cached Medicine Technology:BridgePoint Medical®, Inc. Completes and Submits to FDA in the U.S. FAST-CTOs With the CrossBoss® and Stingray® CTO Recanalization System 2BridgePoint Medical®, Inc. Completes and Submits to FDA in the U.S. FAST-CTOs With the CrossBoss® and Stingray® CTO Recanalization System 3Guidelines on Using Artery-Closing Devices: Devices Are OK, But More Research Needed 2
(Date:8/30/2014)... A new method to predict the optimal number ... at ESC Congress today by Dr Benjamin Dahan from ... AEDs located in public places for optimal prevention of ... said: "Out of hospital cardiac arrest is a major ... 50 and 100 per 100 000 in the general ...
(Date:8/30/2014)... Sunday 31 August 2014: Local anaesthetic is as safe ... general anaesthetic, according to results of the FRANCE 2 ... Chopard from France. , Dr Chopard said: "Numerous studies ... for patients with severe symptomatic aortic stenosis who are ... aortic valve replacement. The number of TAVI procedures in ...
(Date:8/30/2014)... A retrievable and repositionable transcatheter aortic valve is ... according to research presented at ESC Congress 2014 ... direct flow medical (DFM) transcatheter aortic valve has ... the potential to improve transcatheter aortic valve implantation ... , Dr Pyxaras said: "TAVI is well established ...
(Date:8/30/2014)... 31 August 2014: A new batteryless cardiac pacemaker ... heart motion was presented at ESC Congress 2014 ... device does not require battery replacement. , Mr ... Group at ARTORG, University of Bern, Switzerland, said: ... implants. Once they reach a critically low energy ...
(Date:8/30/2014)... 31, 2014 Walking-Canes.Net has released ... a mobility device can help in making gait problems easier. ... download from the website that contains all of the news ... site. , The articles deal with diseases that make walking ... walking cane can help in making life easier for the ...
Breaking Medicine News(10 mins):Health News:New method predicts optimal number and location of AEDs 2Health News:Local anesthetic for TAVI as safe and effective as general anesthetic 2Health News:Retrievable transcatheter aortic valve effective and safe in real world setting 2Health News:Batteryless cardiac pacemaker is based on automatic wristwatch 2Health News:Information Articles on Gait Problems from Walking-Canes.Net 2
... earlier use of antibiotics for blood infection , , TUESDAY, ... in Spain to promote appropriate care for severe sepsis ... adherence and a lower rate of sepsis deaths in ... accounts for one in five admissions to intensive care ...
... giving again, experts warn , , TUESDAY, May 20 (HealthDay News) ... time of decreasing blood donations, a new study shows that ... 17-year-olds, are more likely to bruise, faint or experience other ... of young donors may be less likely to give in ...
... A new 12-week study2examined safety and efficacy ... (budesonide/formoterol fumarate dehydrate) Inhalation Aerosol,2 in treating mild ... to 15 years old2 who were previously treated ... study included efficacy assessments of nighttime symptoms, nighttime ...
... Vista Partners announced today that,it has initiated ... ).,Ross Silver, Director of Research of Vista Partners ... encouraging,clinical and preclinical data to date. Cethrin would ... to Cethrin, Alseres has a molecular,imaging program in ...
... May 20 Ambulatory Services of,America, Inc. announced ... fourth,joint venture to provide outpatient radiation oncology services. ... Cancer Center, LP and ASA,s,subsidiary, Radiation Oncology Services ... operate a radiation therapy facility in Denton, Texas ...
... the thought of baring your,pasty, dry, winter skin makes ... from the International SPA Association have you,covered with some ... in,time for summer! There,s no doubt you,ll be turning ... ISPA member spa prepping for the hot months,ahead., ...
Cached Medicine News:Health News:Educational Drive Cut Death Rate From Sepsis 2Health News:Teen Blood Donors More Prone to Complications 2Health News:Teen Blood Donors More Prone to Complications 3Health News:Study analyzed SYMBICORT in children with persistent asthma 2Health News:Study analyzed SYMBICORT in children with persistent asthma 3Health News:Vista Partners Initiates Coverage on Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE) 2Health News:Ambulatory Services of America, Inc. Announces Joint Venture With Denton Cancer Center, LP 2Health News:10 Ways to Stay Cool This Summer With Hot Spa Products and Treatments 2Health News:10 Ways to Stay Cool This Summer With Hot Spa Products and Treatments 3
... is based on SIREMOBIL Iso-C, the first ... the intra-operative 3D-Mode, the 3D-dataset is immediately ... orbital movement. This allows the surgeon to ... during the procedure. This 3D capability is ...
... Humphrey Field Analyzer II-i series is a ... the patient's visual field. ,By using SITA, ... is reduced by up to 70%. ,A ... ergonomic design to increase patient comfort while ...
... an innovative device designed to be a ... abdominal aortic aneurysms (AAA). It is constructed ... an outer self-expanding Nitinol support structure to ... The function of the endoprosthesis is to ...
... a cast from an arm or leg can ... cut or burned by the cast saw blade. ... remove any cast with confidence. This innovative, cut-resistant ... burns from the cast saw and can be ...
Medicine Products: